News

Align Technology to Report Q3 Earnings: What's in the Cards?

ALGN's Q3 earnings may benefit from Clear Aligner growth and digital innovations, while capital equipment market challenges could weigh on results.

Yahoo·08:08

Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows

WALTHAM, Mass., October 20, 2026--Revvity, Inc. (NYSE: RVTY), announced that its Revvity Signals Software business is launching the Signals LabGistics™ solution, an AI-first, scientific workflow orchestration solution designed to connect and coordinate processes, workflows, and tasks from discovery to manufacturing.

Yahoo·08:00RVTY

Revvity (RVTY), What Is Drawing Fresh Attention Now?

Revvity (RVTY) is back on investor calendars after announcing third quarter 2026 results are due on 3 November, with earnings per share expected to be higher and fresh conference appearances scheduled soon after. Revvity’s share price has surged over the past quarter, with a 30 day share price return of 18.4% and a 90 day gain of 36.2%. The 1 year total shareholder return of 65.6% contrasts with a weaker 5 year total shareholder return that is still down 12.8%, suggesting momentum has...

Yahoo·07:15RVTY

Revvity (RVTY) Stock Could Be 12% Stretched On Cash Flow

Revvity has delivered a strong share price run over the past year, and the key issue now is whether that market enthusiasm lines up with the cash the business can realistically generate. With the stock recently closing at US$152.12, investors are asking if the current tag fairly reflects the company’s underlying cash flows or if expectations are stretching ahead of what the business can support. Over the past 12 months, Revvity has returned 65.6%, which puts real weight on the question of...

Yahoo·21:15RVTY

Here's How Much $100 Invested In Revvity 15 Years Ago Would Be Worth Today

Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.91% on an annualized basis producing an average annual return of 15.11%. Currently, Revvity has a market capitalization of $17.36 billion.

Benzinga·15:15RVTY

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass., October 13, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:

Yahoo·08:00RVTY

TD Cowen Maintains Buy on Revvity, Raises Price Target to $175

TD Cowen analyst Dan Brennan maintains Revvity (NYSE:RVTY) with a Buy and raises the price target from $130 to $175.

Benzinga·07:48RVTY

Cell-Based Assay & High Content Screening Market Report Reveals Why Technology Is Outpacing the Market, Profiling Thermo Fisher, Roche, Sartorius, Revvity & 50 Other Key Players

281-Page Report Tracks Post-Pandemic Research Growth Across Pharma, Research and Industry/Cosmetic Users as 3D Assays, Automation and Immuno-oncology Reshape Drug DiscoveryDublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Cell-Based Assay & High Content Screening Market 2025-2029 - Forecasts by User and Product, with Executive and Consultant Guides" has been added to ResearchAndMarkets.com's offering. Research and Markets has published Cell-Based Assay & High Content Screening Market 2025-2029 - Foreca

Yahoo·07:46RVTY

Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $160

Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and raises the price target from $115 to $160.

Benzinga·07:21RVTY

Revvity Earnings Preview: What to Expect

Revvity will release its third-quarter earnings next month, and analysts anticipate a high single-digit bottom-line growth.

Yahoo·04:54RVTY

Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?

Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Yahoo·12:40RVTY

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.

Yahoo·09:12RVTY

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection

Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.

Yahoo·09:09RVTY

Full Transcript: Revvity Q2 2026 Earnings Call

Revvity (NYSE:RVTY) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For

Benzinga·01:22RVTY

Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years

Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.72%. Currently, Revvity has a market capitalization of $16.82 billion.

Benzinga·13:45RVTY

Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test

All three major US stock indexes fell in late-morning trading Thursday amid uncertainty in the Middl

Yahoo·12:06RVTY

Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes

WALTHAM, Mass., September 24, 2026--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear.

Yahoo·08:00RVTY

Revvity Rolls Out GSP T1D 3plex Kit

Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that

Benzinga·04:03RVTY

Is Revvity Stock Outperforming the Dow?

Revvity has notably outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.

Yahoo·06:33RVTY

Why Revvity (RVTY) Is Getting Attention Today

Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...

Yahoo·22:12RVTY

1 Momentum Stock with Promising Prospects and 2 Facing Headwinds

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

Yahoo·04:17

Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years

Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.61%. Currently, Revvity has a market capitalization of $16.24 billion.

Benzinga·13:15RVTY

Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?

Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo·05:14RVTY

Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.

Yahoo·09:35RVTY

Stocks making the biggest moves midday: Skyworks Solutions, Axon, Dave & Buster's, Revvity & more

These are the stocks posting the largest moves midday.

CNBC·08:03RVTY

Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript

Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor...

SeekingAlpha·07:51RVTY

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical validation across Nu.Q NETs, Nu.Q Cancer, and Capture-Seq. Management has simultaneously decreased operating expenses, which were reduced in the most recent

Yahoo·12:17

3 Healthcare Stocks That Fall Short

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.

Yahoo·11:23

Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SeekingAlpha·07:31RVTY

Revvity to Acquire Human Cell Design to Boost Metabolic Discovery

RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.

Yahoo·11:19RVTY

The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call

Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to "tangible signs of a more constructive spending environmen

Yahoo·22:21RVTY

Revvity (RVTY) Q2 2026 Earnings Call Transcript

Diagnostics surged 11% organically as AI-driven demand accelerated.

Yahoo·13:14RVTY

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass., August 11, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:

Yahoo·08:00RVTY

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

WALTHAM, Mass., August 10, 2026--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.

Yahoo·08:00RVTY

1 Profitable Stock on Our Buy List and 2 We Find Risky

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Yahoo·07:17

Revvity Q2 Earnings Call Highlights

Revvity (NYSE:RVTY) reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows

Yahoo·00:03RVTY

Does Revvity’s Q2 Beat, Higher Guidance and China Exit Alter the Bull Case for RVTY?

Revvity, Inc. reported past second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million and diluted EPS from continuing operations of US$0.48, while also reaffirming a regular US$0.07 per-share quarterly dividend and issuing full-year 2026 revenue guidance of US$2.83 billion to US$2.86 billion. Management attributed the earnings beat and raised outlook to improving pharma and biotech spending, strong Diagnostics growth, especially in reproductive health and...

Yahoo·20:17RVTY